GlassScriptPhysician profile
Debra P Krieg
NPI 1750373106
$4,909.66
in general payments reported to CMS, 2019-2025
32 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $423 · 2021: $483 · 2022: $640 · 2023: $903 · 2024: $1,000 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.30 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,204.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $769.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $566.99 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $453.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $337.67 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $193.70 | 2020-2025 | Livalo, Zoryve, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.16 | 2019-2024 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $147.40 | 2020-2025 | Nexletol, Contrave, Nexlizet |
| Amgen INC. | $114.05 | 2024-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.30 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $86.86 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $78.71 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $78.31 | 2022 | |
| Allergan, INC. | $60.08 | 2020 | |
| Merck Sharp & Dohme LLC | $57.25 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $49.69 | 2025 | Korlym |
| Eisai INC. | $46.65 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $45.90 | 2020-2021 | |
| Exact Sciences Corporation | $33.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $31.67 | 2020 | |
| Amarin Pharma, INC. | $28.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.34 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $25.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.70 | 2021-2022 | |
| Abbott Laboratories | $24.06 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $22.08 | 2019 | |
| Neos Therapeutics, LP | $21.59 | 2019 | |
| Lupin INC. | $20.95 | 2019 | |
| Genentech USA, INC. | $19.06 | 2020 | |
| Azurity Pharmaceuticals, INC. | $13.52 | 2023 | Horizant |
| Shield Therapeutics INC | $12.81 | 2023 | Accrufer |
| Vistapharm, INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Krieg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.